Hartsink-Segers S A, Beaudoin J J, Luijendijk M W J, Exalto C, Pieters R, Den Boer M L
Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands.
1] Department of Pediatric Oncology/Hematology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands [2] Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Leukemia. 2015 Feb;29(2):304-11. doi: 10.1038/leu.2014.210. Epub 2014 Jul 3.
Both tumour suppressor and oncogenic functions have been ascribed to the atypical zeta isoform of protein kinase C (PKCζ), whereas its constitutively active form PKMζ is almost exclusively expressed in the brain where it has a role in long-term memory. Using primers unique for either isoform, we found that both PKCζ and PKMζ were expressed in a subset of paediatric acute lymphoblastic leukaemia (ALL) cases carrying a TCF3 (E2A) chromosomal rearrangement. Combined PKCζ and PKMζ (PKC/Mζ) protein as well as phosphorylation levels were elevated in ALL cases, especially TCF3-rearranged precursor B-ALL cases, compared with normal bone marrow (P<0.01). Furthermore, high PKC/Mζ expression in primary ALL cells was associated with increased sensitivity to 6-thioguanine and 6-mercaptopurine (P<0.01), thiopurines used in ALL treatment. PKCζ is believed to stabilize mismatch-repair protein MSH2, facilitating thiopurine responsiveness in T-ALL. However, PKC/Mζ knockdown in a TCF3-rearranged cell line model decreased MSH2 expression but did not induce thiopurine resistance, indicative that the link between high PKC/Mζ levels and thiopurine sensitivity in paediatric precursor B-ALL is not directly causal. Collectively, our data indicate that thiopurine treatment may be effective, especially in paediatric TCF3-rearranged ALL and other patients with a high expression of PKC/Mζ.
肿瘤抑制和致癌功能都归因于蛋白激酶C(PKCζ)的非典型ζ亚型,而其组成型活性形式PKMζ几乎只在大脑中表达,在长期记忆中发挥作用。使用针对任一亚型的独特引物,我们发现PKCζ和PKMζ在携带TCF3(E2A)染色体重排的小儿急性淋巴细胞白血病(ALL)病例的一个亚组中表达。与正常骨髓相比,ALL病例,尤其是TCF3重排的前体B-ALL病例中,PKCζ和PKMζ(PKC/Mζ)的组合蛋白以及磷酸化水平升高(P<0.01)。此外,原发性ALL细胞中高PKC/Mζ表达与对6-硫鸟嘌呤和6-巯基嘌呤(P<0.01)的敏感性增加相关,6-硫鸟嘌呤和6-巯基嘌呤是ALL治疗中使用的硫嘌呤。据信PKCζ可稳定错配修复蛋白MSH2,促进T-ALL中的硫嘌呤反应性。然而,在TCF3重排的细胞系模型中敲低PKC/Mζ可降低MSH2表达,但不会诱导硫嘌呤抗性,这表明小儿前体B-ALL中高PKC/Mζ水平与硫嘌呤敏感性之间的联系不是直接因果关系。总体而言,我们的数据表明硫嘌呤治疗可能有效,尤其是在小儿TCF3重排的ALL和其他PKC/Mζ高表达的患者中。